[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2013004508A - Moduladores del receptor nicotinico alfa-7 para el tratamiento del dolor, un transtorno psicotico, deterioro cognitivo o enfermedad de alzheimer. - Google Patents

Moduladores del receptor nicotinico alfa-7 para el tratamiento del dolor, un transtorno psicotico, deterioro cognitivo o enfermedad de alzheimer.

Info

Publication number
MX2013004508A
MX2013004508A MX2013004508A MX2013004508A MX2013004508A MX 2013004508 A MX2013004508 A MX 2013004508A MX 2013004508 A MX2013004508 A MX 2013004508A MX 2013004508 A MX2013004508 A MX 2013004508A MX 2013004508 A MX2013004508 A MX 2013004508A
Authority
MX
Mexico
Prior art keywords
alzheimer
pain
alpha
disease
treatment
Prior art date
Application number
MX2013004508A
Other languages
English (en)
Inventor
David Dean
Andrew Lightfoot
Susan Roomans
Original Assignee
Proximagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proximagen Ltd filed Critical Proximagen Ltd
Publication of MX2013004508A publication Critical patent/MX2013004508A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen los compuestos que modulan el receptor de acetilcolina nicotínico a7 (nAChR), que tienen la fórmula (I) en donde las variables son como se especifica en la descripción y en las reivindicaciones.
MX2013004508A 2010-10-27 2011-10-26 Moduladores del receptor nicotinico alfa-7 para el tratamiento del dolor, un transtorno psicotico, deterioro cognitivo o enfermedad de alzheimer. MX2013004508A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40720710P 2010-10-27 2010-10-27
GB201106829A GB201106829D0 (en) 2011-04-21 2011-04-21 Heterocyclic compounds
PCT/EP2011/068807 WO2012055942A1 (en) 2010-10-27 2011-10-26 Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2013004508A true MX2013004508A (es) 2013-08-01

Family

ID=44147409

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004508A MX2013004508A (es) 2010-10-27 2011-10-26 Moduladores del receptor nicotinico alfa-7 para el tratamiento del dolor, un transtorno psicotico, deterioro cognitivo o enfermedad de alzheimer.

Country Status (14)

Country Link
US (1) US9133178B2 (es)
EP (1) EP2632918A1 (es)
JP (1) JP5818901B2 (es)
KR (1) KR20140015267A (es)
CN (1) CN103328468A (es)
AU (1) AU2011322562B2 (es)
BR (1) BR112013010312A2 (es)
CA (1) CA2815910A1 (es)
EA (1) EA023137B1 (es)
GB (1) GB201106829D0 (es)
IL (1) IL225770A0 (es)
MX (1) MX2013004508A (es)
SG (1) SG189499A1 (es)
WO (1) WO2012055942A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111503C2 (uk) 2011-09-27 2016-05-10 Новартіс Аг 3-піримідин-4-іл-оксазолідин-2-они як інгібітори мутантної idh
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
EA201491857A1 (ru) * 2012-05-08 2015-04-30 АНВИЛ ЭлЭлСи АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ α7 НИКОТИНОВОГО ХОЛИНОРЕЦЕПТОРА, ИХ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
EA028033B1 (ru) 2013-03-14 2017-09-29 Новартис Аг 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантного idh
US9550752B2 (en) 2013-04-12 2017-01-24 Bayer Cropscience Aktiengesellschaft Triazolinthione derivatives
CA2909213A1 (en) 2013-04-12 2014-10-16 Bayer Cropscience Aktiengesellschaft Novel triazole derivatives
WO2014167010A1 (en) 2013-04-12 2014-10-16 Bayer Cropscience Ag Novel triazole derivatives
RU2547844C1 (ru) * 2013-10-29 2015-04-10 Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук Способ получения 5-(гет)арил-4-(2-тиенил)-2-(тио)морфолилпиримидина
US9944636B2 (en) 2013-12-11 2018-04-17 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
WO2016156294A1 (en) 2015-04-02 2016-10-06 Bayer Cropscience Aktiengesellschaft Triazol derivatives as fungicides
EP3277666A1 (en) 2015-04-02 2018-02-07 Bayer CropScience Aktiengesellschaft Novel 5-substituted imidazole derivatives
PT3345909T (pt) 2015-08-19 2020-07-29 Astellas Pharma Inc Composto de tetra-hidrooxepinopiridina
TWI806832B (zh) * 2016-07-12 2023-07-01 美商銳新醫藥公司 作為異位shp2抑制劑之2,5-雙取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪
KR20190052007A (ko) 2016-09-13 2019-05-15 바이엘 크롭사이언스 악티엔게젤샤프트 5-치환된 이미다졸 유도체를 포함하는 활성 화합물 조합물
EP3519392A1 (en) 2016-09-29 2019-08-07 Bayer CropScience Aktiengesellschaft Novel 5-substituted imidazole derivatives
US20200039973A1 (en) 2016-09-29 2020-02-06 Bayer Cropscience Aktiengesellschaft Novel 5-substituted imidazolylmethyl derivatives
EP3519408A1 (en) 2016-09-29 2019-08-07 Bayer CropScience Aktiengesellschaft 1 -[2-(1 -chlorocyclopropyl)-2-hydroxy-3-(3-phenyl-1,2-oxazol-5-yl)propyl]-1h-imidazole-5-carbonitrile derivatives and related compounds as fungicides for crop protection
WO2018083136A1 (en) 2016-11-03 2018-05-11 F. Hoffmann-La Roche Ag Novel tetrahydroisoquinolines and terahydronaphthyridines for the treatment and prophylaxis of hepatitis b virus infection
EP3571199A1 (en) 2017-01-23 2019-11-27 Revolution Medicines, Inc. Bicyclic compounds as allosteric shp2 inhibitors
BR112019014527A2 (pt) 2017-01-23 2020-02-27 Revolution Medicines, Inc. Compostos de piridina como inibidores de shp2 alostéricos
CN107311988B (zh) * 2017-07-15 2018-08-21 上海普康药业有限公司 一种治疗阿尔茨海默病的药物
KR20200051684A (ko) 2017-09-07 2020-05-13 레볼루션 메디슨즈, 인크. 암 치료를 위한 shp2 억제제 조성물 및 방법
RU2020115095A (ru) 2017-10-12 2021-11-12 Революшн Медсинз, Инк. Пиридиновые, пиразиновые и триазиновые соединения в качестве аллостерических ингибиторов shp2
US11213031B2 (en) 2017-11-13 2022-01-04 Bayer Aktiengesellschaft Tetrazolylpropyl derivatives and their use as fungicides
KR20200099530A (ko) 2017-12-15 2020-08-24 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 다환식 화합물
KR20210018244A (ko) 2018-05-01 2021-02-17 레볼루션 메디슨즈, 인크. mTOR 억제제로서의 C40-, C28- 및 C-32-연결된 라파마이신 유사체
GB2598768B (en) * 2020-09-11 2024-09-11 Moa Tech Limited Herbicidal heterocyclic derivatives

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3948894A (en) 1974-01-31 1976-04-06 Eli Lilly And Company 3-Amino-5,6-diaryl-1,2,4-triazines
US4513135A (en) 1982-03-05 1985-04-23 Eli Lilly And Company Diaryl-pyrazine derivatives affecting GABA binding
JPH06501926A (ja) 1990-08-06 1994-03-03 藤沢薬品工業株式会社 複素環式化合物
WO1998024782A2 (en) 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidine compounds and their use
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
US7189717B2 (en) 2000-04-26 2007-03-13 Eisai Co., Ltd. Medicinal compositions promoting bowel movement
US6664256B1 (en) 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
US7179912B2 (en) 2000-09-01 2007-02-20 Icos Corporation Materials and methods to potentiate cancer treatment
WO2004029204A2 (en) 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
US7326706B2 (en) * 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
CN101084223A (zh) * 2004-12-20 2007-12-05 阿斯利康(瑞典)有限公司 新吡唑衍生物及其作为烟碱乙酰胆碱受体调节剂的用途
US20070078135A1 (en) * 2005-04-18 2007-04-05 Neurogen Corporation Substituted heteroaryl CB1 antagonists
JO3078B1 (ar) 2009-11-27 2017-03-15 Janssen Pharmaceutica Nv مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة

Also Published As

Publication number Publication date
JP2013540794A (ja) 2013-11-07
KR20140015267A (ko) 2014-02-06
AU2011322562B2 (en) 2015-10-22
EA201370077A1 (ru) 2013-11-29
BR112013010312A2 (pt) 2016-09-20
JP5818901B2 (ja) 2015-11-18
EP2632918A1 (en) 2013-09-04
US9133178B2 (en) 2015-09-15
SG189499A1 (en) 2013-05-31
EA023137B1 (ru) 2016-04-29
US20130310380A1 (en) 2013-11-21
CA2815910A1 (en) 2012-05-03
GB201106829D0 (en) 2011-06-01
AU2011322562A1 (en) 2013-05-09
WO2012055942A1 (en) 2012-05-03
IL225770A0 (en) 2013-06-27
CN103328468A (zh) 2013-09-25

Similar Documents

Publication Publication Date Title
MX2013004508A (es) Moduladores del receptor nicotinico alfa-7 para el tratamiento del dolor, un transtorno psicotico, deterioro cognitivo o enfermedad de alzheimer.
MY161854A (en) Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
MY160907A (en) Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
EA201290310A1 (ru) Производные имидазолидиндиона
MX2018015635A (es) Composiciones y metodos para la modulacion de division de smn2 en un sujeto.
MX2010002674A (es) Moduladores de gamma secretasa.
MY169497A (en) Selective heterocyclic sphingosine 1 phosphate receptor modulators
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
MX2010006379A (es) Moduladores de la secretasa gamma.
MX2012000973A (es) Compuestos para la reduccion de produccion de beta- amiloide.
MX2020012825A (es) Compuestos multiciclicos y metodos de uso de los mismos.
MX2012003539A (es) Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).
MX356644B (es) Derivados de 2-fenilaminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
HK1150555A1 (zh) 用於治療動脈硬化的 -嘧啶二元胺的應用
MX2010005028A (es) Moduladores de gamma secretasa.
WO2012019106A3 (en) Compounds for use in modulating the nmda receptor
WO2012158550A3 (en) Selective heterocyclic sphingosine 1 phosphate receptor modulators
IN2014DN07636A (es)
MX2012015305A (es) Compuestos heterociclicos, su preparacion y su aplicacion terapeutica.
EP2416795A4 (en) COGNITIVE DECLINE INHIBITORS
EP2219666A4 (en) PROSTATE ACID PHOSPHATASE FOR THE TREATMENT OF PAIN
MX2013008699A (es) Compuestos para reducir la produccion de beta-amiloide.
MX2010001501A (es) Moduladores de gamma secretasa.
IL207668A0 (en) Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
WO2010147969A3 (en) Gamma secretase modulators

Legal Events

Date Code Title Description
FA Abandonment or withdrawal